Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03LWG
|
||||
| Former ID |
DNCL002160
|
||||
| Drug Name |
BGJ398
|
||||
| Synonyms |
FGFR inhibitors
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 2 | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H31Cl2N7O3
|
||||
| InChI |
InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)
|
||||
| InChIKey |
QADPYRIHXKWUSV-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
124359248, 135610369, 136023525, 136348830, 136362079, 136946568, 137167188, 137602343, 144115702, 152159552, 152258531, 160647365, 162011595, 162205151, 163642798, 164034385, 164043528, 164193926, 172914340, 174006580, 174531137, 175426349, 177749165, 185975410, 189561513, 196409720, 198987912, 223366206, 223471433, 223705030, 224624345, 226706104, 242059884, 242459086, 248480244, 252160439, 252214977, 252449171, 252451765, 252543423, 252672020
|
||||
| Target and Pathway | |||||
| Target(s) | Basic fibroblast growth factor receptor 1 | Target Info | Modulator | [3] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Ras signaling pathway | |||||
| Rap1 signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| Adherens junction | |||||
| Signaling pathways regulating pluripotency of stem cells | |||||
| Regulation of actin cytoskeleton | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| Prostate cancer | |||||
| Melanoma | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| FGF signaling pathway | |||||
| Pathway Interaction Database | Glypican 1 network | ||||
| Syndecan-4-mediated signaling events | |||||
| N-cadherin signaling events | |||||
| FGF signaling pathway | |||||
| WikiPathways | Regulation of Actin Cytoskeleton | ||||
| Endochondral Ossification | |||||
| MAPK Signaling Pathway | |||||
| Mesodermal Commitment Pathway | |||||
| Hair Follicle Development: Induction (Part 1 of 3) | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Signaling Pathways in Glioblastoma | |||||
| Neural Crest Differentiation | |||||
| Signaling by FGFR | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02160041) BGJ398 for Patients With Tumors With FGFR Genetic Alterations. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7877). | ||||
| REF 3 | Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.